Chiesi Group and Bespak announce an expansion of their partnership to increase pressurised metered dose inhaler manufacturing capacity in the UK, at the Bespak site in Holmes Chapel, Cheshire.
It will help to deliver lower carbon inhaled therapies for asthma and Chronic Obstructive Pulmonary Disease patients at scale – without compromising clinical choice or care continuity.
Chiesi is working to offer a portfolio of extrafine formulation Carbon Minimal Inhalers – including dry powder and next generation propellant pressurised metered dose inhalers – and reduce the carbon footprint of pressurised metered dose inhalers by up to 90%.
Positioned in the North West of England’s inhalation R&D and manufacturing cluster, the site contributes high value skills, advanced technical expertise and long-term investment in sustainable inhaler manufacturing, for the benefit of patients and healthcare systems worldwide.
Maria Paola Chiesi, Chiesi Group Vice Chair, said: “At Chiesi, sustainability is not an add-on; it is a commitment that guides our strategic choices. We know that inhalers are essential treatments, and that the environmental impact associated with them must be addressed without shifting the burden onto patients.
The partnership with Bespak reinforces our efforts to reduce emissions across the value chain, while protecting access, quality and trust. Climate action and patient care must continue to advance hand in hand.”
Giuseppe Accogli, Chiesi Group CEO, said: “This agreement strengthens an already established partnership with Bespak, and is a concrete example of how we translate our ambition into action. By working with trusted partners across our value chain, we can deliver sustainable innovation at scale while ensuring that patients receive their needed therapies.”
The partnership with Bespak reinforces our efforts to reduce emissions across the value chain, while protecting access, quality and trust. Climate action and patient care must continue to advance hand in hand.”
Giuseppe Accogli, Chiesi Group CEO, said: “This agreement strengthens an already established partnership with Bespak, and is a concrete example of how we translate our ambition into action. By working with trusted partners across our value chain, we can deliver sustainable innovation at scale while ensuring that patients receive their needed therapies.”
Chris Hirst, Bespak CEO, said: “By deepening this partnership, we are accelerating the transition to low carbon pMDIs and reinforcing the UK’s role as a centre of excellence for sustainable inhalation manufacturing. This is a position being recognised by the wider industry, leading to our Holmes Chapel site being selected as a key source of supply by leading brand owners like Chiesi, cementing our role as a strategic supply chain partner for the next generation propellant inhalers and innovative nasally-delivered therapies.”